Asset Details
Do you wish to reserve the book?
Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients
Do you wish to request the book?
Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients
2019
Overview
Background
Although beta blockers could increase the risk of hypoglycemia, the difference between subtypes on hypoglycemia and mortality have not been studied. This study sought to determine the relationship between type of beta blocker and incidence of hypoglycemia and mortality in hospitalized patients.
Methods
We retrospectively identified non-critically ill hospitalized insulin requiring patients who were undergoing bedside glucose monitoring and received either carvedilol or a selective beta blocker (metoprolol or atenolol). Patients receiving other beta blockers were excluded. Hypoglycemia was defined as any glucose < 3.9 mmol/L within 24 h of admission (Hypo
1day
) or throughout hospitalization (Hypo
T
) and any glucose < 2.2 mmol/L throughout hospitalization (Hypo
severe
).
Results
There were 1020 patients on carvedilol, 886 on selective beta blockers, and 10,216 on no beta blocker at admission. After controlling for other variables, the odds of Hypo
1day,
Hypo
T
and Hypo
severe
were higher for carvedilol and selective beta blocker recipients than non-recipients, but only in basal insulin nonusers. The odds of Hypo
1day
(odds ratio [OR] 1.99, 95% confidence interval [CI] 1.28, 3.09, p = 0.0002) and Hypo
T
(OR 1.38, 95% CI 1.02, 1.86, p = 0.03) but not Hypo
severe
(OR 1.90, 95% CI 0.90, 4.02, p = 0.09) were greater for selective beta blocker vs. carvedilol recipients in basal insulin nonusers. Hypo
1day
, Hypo
T
, and Hypo
severe
were all associated with increased mortality in adjusted models among non-beta blocker and selective beta blocker recipients, but not among carvedilol recipients.
Conclusions
Beta blocker use is associated with increased odds of hypoglycemia among hospitalized patients not requiring basal insulin, and odds are greater for selective beta blockers than for carvedilol. The odds of hypoglycemia-associated mortality are increased with selective beta blocker use or nonusers but not in carvedilol users, warranting further study.
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
Adrenergic beta-Antagonists - administration & dosage
/ Adrenergic beta-Antagonists - adverse effects
/ Aged
/ Atenolol
/ Atenolol - administration & dosage
/ Blood Glucose - drug effects
/ Carvedilol - administration & dosage
/ Carvedilol - adverse effects
/ Diabetes
/ Female
/ Glucose
/ Humans
/ Hypoglycemia - chemically induced
/ Hypoglycemic Agents - administration & dosage
/ Hypoglycemic Agents - adverse effects
/ Insulin
/ Insulin - administration & dosage
/ Male
/ Medicine
/ Metoprolol - administration & dosage
/ Metoprolol - adverse effects
/ Patients
/ Studies
